Track topics on Twitter Track topics that are important to you
This study will investigate the effectiveness of combination of carboplatin and investigational agent RAD001 in triple-negative breast cancer.
This study is an open label phase II trial of carboplatin and RAD001 in women with triple-negative breast cancer. Carboplatin, at a dose of AUC 6, will be given as an IV infusion every three weeks. RAD001 will be given as a 5 mg pill daily with a run in of 3 patients. If there is a dose limiting toxicity (any toxicity requiring dose modification or interruption as per table 3.1) among the first 3 patients, that number will be increased to 6 patients. If the 5 mg dose is found to be tolerable among the first 3 patients, the RAD001 dose will be increased to a 10 mg pill daily. In the unexpected case of 2 or more DLT's at 5 mg/day or 1 or more DLT's in the additional 3 patients, further dosing will be reviewed by the PI in conjunction with the NYU DSMC. For any toxicity leading to treatment delays of >7 days, the carboplatin dose will be decreased to AUC of 5 in subsequent cycles, and with subsequent treatment delays >14 days the patient will be taken off the study regimen. Carboplatin will not be reduced for RAD001 related toxicities. Patients will be assessed for response every two cycles with either PET/CT or CT of the chest, abdomen, and pelvis and a bone scan. In addition patients will be followed with serial CEA and CA 27-29 levels. The patients will continue on the protocol until there is progression of disease or unacceptable toxicity.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
NYU Clinical Cancer Center
Not yet recruiting
New York University School of Medicine
Published on BioPortfolio: 2014-08-27T03:13:32-0400
The hypothesis of this clinical research study is to discover if the study drug RAD001 can shrink or slow the growth of ER/PR negative or Her2 Neu negative breast cancer. The safety of RA...
In order to improve the survival of metastatic breast patients, it is important to investigate the use of novel therapeutic agents combined with known active agents in the treatment of bre...
The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.
The purpose of this research study is to determine the safety of RAD001 and the highest dose of this drug that can be given to people with HER2-positive metastatic breast cancer safely in ...
The primary objective of this study is to determine if estrogen receptor-targeted therapy with fulvestrant used in combination with RAD001 (Everolimus) is an effective and safe therapy for...
Small cell lung cancer (SCLC) is a highly malignant cancer with few targeted therapies. In the study, by mining the Cancer Cell Line Encyclopedia (CCLE) database, we found that PI3K/AKT/mTOR pathway w...
The mammalian target of rapamycin (mTOR) pathway is a critical target for cancer treatment and the mTOR inhibitor everolimus (RAD001) has been approved for treatment of renal cell carcinoma (RCC). How...
Gene expression profiling of breast cancer has demonstrated the importance of stromal response in determining the prognosis of invasive breast cancer. The host response to breast cancer is of increasi...
The number of old people with breast cancer is estimated to increase during the next years in developed countries. However, management of breast cancer in octogenarians is not well established. The ma...
The aim of this study was to assess the frequency of second primary non-breast cancer after breast cancer diagnosis and treatment, and its correlation with clinicopathological features.
Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...